Please assess the completion status of the following clinical trial:

Trial Title: Triple Versus Dual Antiplatelet Therapy After ABT578-Eluting Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical 1) Patients with angina and documented ischemia or patients with documented silent ischemia 2) Patients who are eligible for intracoronary stenting 3) Age \>18 years, \<75 ages~2. Angiographic 1) De novo lesion 2) Percent diameter stenosis ≥50% 3) Reference vessel size \>2.5 mm by visual estimation 4) Lesion length \>25 mm by visual estimation that is required for long Endeavor stent implantation (planned total stent length \>30mm)~Exclusion Criteria:~1. History of bleeding diathesis or coagulopathy~2. Pregnant~3. Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus and paclitaxel~4. Limited life-expectancy (less than 1 year) due to combined serious disease~5. ST-elevation acute myocardial infarction~6. Characteristics of lesion 1) Left main disease 2) In-stent restenosis 3) Graft vessels~7. Hematological disease (Neutropenia \<3000/mm3, Thrombocytopenia \<100,000/mm3)~8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation \>3 times normal~9. Renal dysfunction, creatinine \>2.0mg/dL~10. Contraindication to aspirin, clopidogrel or cilostazol~11. planned bifurcation stenting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- cilostazol (Type: EXPERIMENTAL): Cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
- placebo (Type: PLACEBO_COMPARATOR): Control placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months

Based on this trial design, predict the completion outcome and termination type (if applicable).